Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.”In the company’s words, NCT04762225 on ClinicalTrials.gov
Other drugs for Head and Neck Squamous Cell Carcinoma
- APG-157Aveta Biomics, Inc. · Phase 3
- PembrolizumabMerck & Co. · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- FiclatuzumabAVEO Pharmaceuticals, Inc. · Phase 3
- SYS6002CSPC · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 14 Sep 2022 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026